Intellia's Nex-z MAGNITUDE Trial: In-Depth Analysis

Intellia Therapeutics' MAGNITUDE trial, evaluating nexiguran ziclumeran (nex-z) for transthyretin amyloidosis (ATTR), has released updated data. This analysis examines the trial's progress, potential implications, and c…